Instrument Inactif

Communiqués Oxis International Euronext Paris

Actions

US6918294025

Recherche biotechnologique et médicale

Cours en clôture Euronext Paris
- ^EUR	-

14/08	GT Biopharma, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
30/06	GT Biopharma intègre l'intelligence artificielle dans la découverte et l'ingénierie de ses activateurs de cellules NK et protéines multi-domaines	CI

Communiqués

14/08	GT Biopharma Reports Second Quarter 2026 Financial Results	AQ
12/06	After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell	AQ
08/06	Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet	AQ
01/06	GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives	AQ
15/05	GT Biopharma Reports First Quarter 2026 Financial Results	AQ
14/05	"Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming Therapies	AQ
14/05	A Cancer Antigen Long Thought Untouchable Is Suddenly the Hottest Target in Oncology	AQ
14/05	GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors	AQ
11/03	GT Biopharma to Participate in the 38th Annual Roth Conference	AQ
06/03	GT Biopharma : Amendment to Quarterly Report (Form 10-Q/A)	PU
06/03	GT Biopharma : Amendment to Quarterly Report (Form 10-Q/A)	PU
02/03	GT Biopharma Reports Full Year 2025 Financial Results	AQ
17/02	GT Biopharma to Present at the Centurion One Capital 9th Annual Toronto Growth Conference	AQ
09/02	Ellis Martin Report: GT Biopharma, Inc. (NAS:GTBP) Advances Platform Immuno-Oncology Strategy with FDA-Cleared Solid Tumor IND; An Interview with CEO Michael Breen	AQ
03/02	GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-5550 TriKE®, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors Expressing B7-H3	AQ
16/01	GT Biopharma Announces IND Submission for GTB-5550 TriKE, a B7-H3-targeted natural killer cell engager for B7-H3 expressing solid tumor cancers	AQ
15/01	GT Biopharma Announces IND Submission for GTB-5550 TriKE®, a B7-H3-targeted natural killer (NK) cell engager for B7-H3 expressing solid tumor cancers	AQ
24/12	Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge	AQ
19/12	Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030	AQ
04/12	Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points	AQ
17/11	GT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update	AQ
14/11	GT Biopharma : Release Q3 2025	PU
14/11	GT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update	AQ
23/10/25	GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies	AQ
09/10/25	GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory CD33 Expressing Hematologic Malignancies	AQ